<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2954">
  <stage>Registered</stage>
  <submitdate>12/10/2010</submitdate>
  <approvaldate>12/10/2010</approvaldate>
  <nctid>NCT01223352</nctid>
  <trial_identification>
    <studytitle>Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension</studytitle>
    <scientifictitle>An Open-label, Prospective Multicenter Study to Assess the Pharmacokinetics, Tolerability, Safety and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension</scientifictitle>
    <utrn />
    <trialacronym>FUTURE 3</trialacronym>
    <secondaryid>AC-052-373</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pulmonary Arterial Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - bosentan

Experimental: Bosentan 2 mg/Kg t.i.d. - 2 mg/kg bosentan administered three times a day (morning, afternoon, evening) for a planned duration of 24 weeks

Experimental: Bosentan 2 mg/Kg b.i.d. - 2 mg/kg bosentan administered twice daily (morning and evening) for a planned duration of 24 weeks


Treatment: drugs: bosentan
32 mg quadrisected dispersible tablet. The dosage of bosentan (2 mg/Kg) was adjusted according to the patient's body weight at initiation of the study treatment. Dosage readjustment was permitted after 12 weeks of treatment.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Dose-corrected Daily Exposure [AUC(0-24c)] to Bosentan - Daily exposure was measured by the area under the plasma concentration-time curve over a period of 24 hours [AUC(0-24)].
Concentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 8 hours or up to 12 hours post-dose for the t.i.d and b.i.d. dosing regimen, respectively. AUC(0-24) was calculated as a multiple of AUCtau, which is the AUC over a dosing interval (AUCtau x 2 for the b.i.d. dosing regimen and AUCtau x 3 for the t.i.d. regimen). As the smallest dose unit was 8 mg (1/4 tablet), it was not possible to achieve the exact target dose of 2 mg/kg. Therefore, AUC(0-24) was corrected to 2 mg/kg (target dose) [AUC(0-24c)].</outcome>
      <timepoint>0, 0.5, 1, 3, 5 (or 7.5), 8 (or 12 hours) post-dose at Week 4, after at least 2 weeks of stable study drug treatment</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. PAH diagnosis confirmed with right heart catheterization (RHC):

               -  Idiopathic or heritable PAH, or

               -  Associated PAH persisting after complete repair of a congenital heart defect (PAH
                  has to be persistent for at least 6 months after surgery) or

               -  PAH-Congenital Heart Disease (PAH-CHD) associated with systemic-to-pulmonary
                  shunts (after global amendment dated 09 May 2012)

          2. World Health Organization functional Class (WHO FC) I, II or III

          3. Male or female = 3 months and &lt; 12 years of age (maximum age at randomization is 11.5
             years)

          4. Body weight = 3.5 kg

          5. Peripheral oxygen saturation (SpO2) = 88% (at rest, on room air)

          6. Baseline PAH-therapy (Calcium channel blocker, bosentan, prostanoid, phosphodiesterase
             type-5 inhibitor) if present, had to be stable for at least 3 months prior to
             screening. During the study, all background treatments should remain stable

          7. Signed informed consent by the parents or legal representatives</inclusivecriteria>
    <inclusiveminage>3</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>12</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. PAH etiologies other than listed above

          2. Non-stable disease status

          3. Need or plan to wean patient from intravenous epoprostenol or intravenous or inhaled
             iloprost

          4. Systolic blood pressure &lt; 80% of the lower limit of normal range

          5. Aspartate aminotransferase and/or alanine aminotransferase values &gt; 1.5 times the
             upper limit of normal range.

          6. Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C

          7. Hemoglobin and/or hematocrit levels &lt; 75% of the lower limit of normal range.

          8. Known intolerance or hypersensitivity to bosentan or any of the excipients of the
             dispersible Tracleer tablet

          9. Treatment with forbidden medication within 2 weeks or at least 5 times the half-life
             prior to randomization, whichever was the longest:

               -  Glibenclamide (glyburide)

               -  Cyclosporin A

               -  Sirolimus

               -  Tacrolimus

               -  Fluconazole

               -  Rifampicin (rifampin)

               -  Ritonavir

               -  Co-administration of CYP2C9 inhibitors (e.g., amiodarone, voriconazole) and
                  moderate/strong CYP3A4 inhibitors (e.g., amprenavir, erythromycin, ketoconazole,
                  diltiazem, itraconazole)

               -  Endothelin receptor antagonists (ERAs) other than bosentan

         10. Treatment with another investigational drug within 1 month prior to randomization or
             planned treatment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>8/03/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>64</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>19/08/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Children's Hospital Melbourne, Cardiology - Site 5001 - Parkville</hospital>
    <postcode>3052 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belarus</country>
      <state>Minsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Chengdu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Guangdong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Giessen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szeged</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Hyderabad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>New Dehli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petach Tikvah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kemerovo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Bloemfontein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Durban</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Pretoria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Dnepropetrovsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Donetsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kiev</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Actelion</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of AC-052-373 was to assess the pharmacokinetic (PK) profile of two
      dosing regimens of the pediatric formulation of bosentan in children with pulmonary arterial
      hypertension (PAH) &lt;12 years of age.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01223352</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andjela Kusic-Pajic, MD</name>
      <address>Actelion</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>